Acambis requests meeting with US Health Department on smallpox vaccine

|
acambis LONDON (AFX) - Biotechnology company Acambis PLC confirmed that it has requested a meeting with the US Department of Health and Human Services (DHHS) to discuss its rationale for excluding Acambis from the ongoing Modified Vaccinia Ankara (MVA) procurement process.

Acambis is developing an investigational smallpox vaccine, ACAM2000.

DHHS determined that Acambis' technical proposal was no longer in the competitive range for award, and to-date, DHHS has not provided a specific reason for the decision.

In the MVA-related litigation between Acambis and Bavarian Nordic A/S (BN),

the International Trade Commission (ITC) has decided to review the judge's Initial Determination. Acambis received a favourable judgement in September, invalidating the patent claims made against Acambis by BN.

Acambis said it expects a favourable ruling, given the strength of the ruling in September and of the ITC staff's independent view of the case. The final decision is expected in January 2007.

source - AFX